Provectus Pharmaceuticals to Present on PV-10 at AACR

01/23/2013

Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination of PV-10 immuno-chemoablation and systemic anti-CTLA-4 antibody therapy in murine models of melanoma," is authored by Eric Wachter, Savannah Blair, Jamie Singer, and Craig Dees, and will be presented on April 10, 2013. PV-10 is Provectus Pharmaceuticals's novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free